Peer-influenced content. Sources you trust. No registration required. This is HCN.

BloodOral Azacitidine Prolongs Survival of Patients with AML in Remission Independently of Measurable Residual Disease Status

Oral azactidine substantially improved survival compared with placebo irrespective of baseline MRD status, and the survival benefit with oral-AZA relative to placebo was greater in the baseline MRD+ subgroup than in the MRD− subgroup. Multivariate analysis confirmed the significant independent treatment effect of oral-AZA vs. placebo on OS and RFS when controlling for MRD status at baseline.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form